Tirzepatide is the generic name for a medication primarily used to treat type 2 diabetes and is available under the brand names Mounjaro for diabetes management and Zepbound for obesity treatment
Will insurance cover the costs of the medication
Neuroinflammation, oxidative stress and the pathogenesis of Alzheimers disease

Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication

In other words, any potential decrease in PMS symptoms could be an indirect effect of the weight loss experienced with Wegovy or Ozempic
Providers should ask about support systems and whether a person is ready for change